CHELMSFORD, Mass., Nov. 21, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the virtual 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, which includes a presentation beginning at 3:30 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.
Azenta is headquartered in Massachusetts, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.
INVESTOR CONTACTS:
Sara Silverman
Head of Investor Relations
978.262.2635
This email address is being protected from spambots. You need JavaScript enabled to view it.
Sherry Dinsmore
978.262.2400
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$25.50 |
| Daily Change: | -0.41 -1.58 |
| Daily Volume: | 820,392 |
| Market Cap: | US$1.170B |
November 12, 2024 November 04, 2024 October 30, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
